Lowest Price Guaranteed
Pages
253
Last Updated
August 2026
View Count
9466
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Non-Small Cell Lung Cancer
6.3. Types of Non-Small Cell Lung Cancer
6.4. Future Perspectives
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Non-Small Cell Lung Cancer Drug Developers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Company Size and Location of Headquarters
7.2.5. Analysis by Type of Molecule
7.2.6. Analysis by Drug Class
7.2.7. Analysis by Type of Therapy
7.2.8. Analysis by Combination Drug
7.2.9. Analysis by Route of Administration
7.2.10. Analysis by Line of Treatment
7.2.11. Analysis by Target Indication
7.2.12. Analysis by Dosing Frequency
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Amgen
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.3. Recent Initiatives
*Similar details are presented for other companies mentioned below (based on information in the public domain)
8.3. BeiGene
8.4. Genetech
8.5. Roche
9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Non-Small Cell Lung Cancer Market: Patent Analysis
9.3.1. Analysis by Publication Year
9.3.2. Analysis by Type of Patent
9.3.3. Analysis by Type of Patent and Publication Year
9.3.4. Analysis by Type of Applicant
9.3.5. Analysis by Application Year
9.3.6. Analysis by Patent Jurisdiction (Region)
9.3.7. Analysis by Patent Jurisdiction (Country)
9.3.8. Analysis by Patent Age
9.3.9. Leading Industry Players: Analysis by Number of Patents
9.3.10. Leading Non-Industry Players: Analysis by Number of Patents
9.3.11. Leading Individual Assignees: Analysis by Number of Patents
9.3.12. Analysis by CPC Symbols
9.4. Non-Small Cell Lung Cancer: Patent Benchmarking Analysis
9.5. Patent Valuation Analysis
10. MARKET IMPACT ANALYSIS
10.1. Chapter Overview
10.2. Market Drivers
10.3. Market Restraints
10.4. Market Opportunities
10.5. Market Challenges
10.6. Conclusion
11. MEGA TREND ANALYSIS
12. GLOBAL NON-SMALL CELL LUNG CANCER MARKET
12.1. Chapter Overview
12.2. Assumptions and Methodology
12.3. Global Non-Small Cell Lung Cancer Market, Forecasted Estimates (till 2035)
12.4. Roots Analysis Perspective on Market Growth
12.5. Scenario Analysis
12.5.1. Conservative Scenario
12.5.2. Optimistic Scenario
12.6. Key Market Segmentations
13. NON-SMALL CELL LUNG CANCER MARKET, BY TYPE OF CANCER
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Non-Small Cell Lung Cancer Market: Distribution by Type of Cancer
13.3.1. Non-Small Cell Lung Cancer Market for Squamous Cell Carcinoma, Forecasted Estimates (till 2035)
13.3.2. Non-Small Cell Lung Cancer Market for Adenocarcinoma, Forecasted Estimates (till 2035)
13.3.3. Non-Small Cell Lung Cancer Market for Large Cell Neuroendocrine Tumors, Forecasted Estimates (till 2035)
13.3.4. Non-Small Cell Lung Cancer Market for Large-Cell Carcinoma, Forecasted Estimates (till 2035)
13.4. Data Triangulation and Validation
14. NON-SMALL CELL LUNG CANCER MARKET, BY TYPE OF MOLECULE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Non-Small Cell Lung Cancer Market: Distribution by Type of Molecule
14.3.1. Non-Small Cell Lung Cancer Market for Small Molecules, Forecasted Estimates (till 2035)
14.3.2. Non-Small Cell Lung Cancer Market for Biologics, Forecasted Estimates (till 2035)
14.4. Data Triangulation and Validation
15. NON-SMALL CELL LUNG CANCER MARKET, BY TYPE OF DRUG CLASS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Non-Small Cell Lung Cancer Market: Distribution by Type of Drug Class
15.3.1. Non-Small Cell Lung Cancer Market for Alkylating Agents, Forecasted Estimates (till 2035)
15.3.2. Non-Small Cell Lung Cancer Market for Antimetabolites, Forecasted Estimates (till 2035)
15.3.3. Non-Small Cell Lung Cancer Market for EGFR Inhibitors, Forecasted Estimates (till 2035)
15.3.4. Non-Small Cell Lung Cancer Market for Mitotic Inhibitors, Forecasted Estimates (till 2035)
15.3.5. Non-Small Cell Lung Cancer Market for Multi-kinase Inhibitors, Forecasted Estimates (till 2035)
15.3.6. Non-Small Cell Lung Cancer Market for Others, Forecasted Estimates (till 2035)
15.4. Data Triangulation and Validation
16. NON-SMALL CELL LUNG CANCER MARKET, BY TYPE OF THERAPY
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Non-Small Cell Lung Cancer Market: Distribution by Type of Therapy
16.3.1. Non-Small Cell Lung Cancer Market for Monotherapies, Forecasted Estimates (till 2035)
16.3.2. Non-Small Cell Lung Cancer Market for Combination Therapies, Forecasted Estimates (till 2035)
16.4. Data Triangulation and Validation
17. NON-SMALL CELL LUNG CANCER MARKET, BY TYPE OF TREATMENT
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Non-Small Cell Lung Cancer Market: Distribution by Type of Treatment
17.3.1. Non-Small Cell Lung Cancer Market for Chemotherapy, Forecasted Estimates (till 2035)
17.3.2. Non-Small Cell Lung Cancer Market for Radiation Therapy, Forecasted Estimates (till 2035)
17.3.3. Non-Small Cell Lung Cancer Market for Targeted Therapy, Forecasted Estimates (till 2035)
17.3.4. Non-Small Cell Lung Cancer Market for Immunotherapy, Forecasted Estimates (till 2035)
17.3.5. Non-Small Cell Lung Cancer Market for Other Treatments, Forecasted Estimates (till 2035)
17.4. Data Triangulation and Validation
18. NON-SMALL CELL LUNG CANCER MARKET, BY ROUTE OF ADMINISTRATION
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Non-Small Cell Lung Cancer Market: Distribution by Route of Administration
18.3.1. Non-Small Cell Lung Cancer Market for Parenteral, Forecasted Estimates (till 2035)
18.3.2. Non-Small Cell Lung Cancer Market for Oral, Forecasted Estimates (till 2035)
18.3.3. Non-Small Cell Lung Cancer Market for Other Route of Administration, Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation
19. NON-SMALL CELL LUNG CANCER MARKET, BY END USER
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Non-Small Cell Lung Cancer Market: Distribution by End User
19.3.1. Non-Small Cell Lung Cancer Market for Hospitals, Forecasted Estimates (till 2035)
19.3.2. Non-Small Cell Lung Cancer Market for Homecare, Forecasted Estimates (till 2035)
19.3.3. Non-Small Cell Lung Cancer Market for Specialty Clinics, Forecasted Estimates (till 2035)
19.3.4. Non-Small Cell Lung Cancer Market for Other End Users, Forecasted Estimates (till 2035)
19.4. Data Triangulation and Validation
20. NON-SMALL CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Non-Small Cell Lung Cancer Market: Distribution by Distribution Channel
20.3.1. Non-Small Cell Lung Cancer Market for Hospital Pharmacies, Forecasted Estimates (till 2035)
20.3.2. Non-Small Cell Lung Cancer Market for Drugs and Retail Pharmacies, Forecasted Estimates (till 2035)
20.3.3. Non-Small Cell Lung Cancer Market for Online Pharmacies, Forecasted Estimates (till 2035)
20.4. Data Triangulation and Validation
21. NON-SMALL CELL LUNG CANCER MARKET, BY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Non-Small Cell Lung Cancer Market: Distribution by Geographical Regions
21.3.1. Non-Small Cell Lung Cancer Market in North America: Forecasted Estimates (till 2035)
21.3.2. Non-Small Cell Lung Cancer Market in Europe: Forecasted Estimates (till 2035)
21.3.3. Non-Small Cell Lung Cancer Market in Asia-Pacific: Forecasted Estimates (till 2035)
21.3.4. Non-Small Cell Lung Cancer Market in Middle East and North Africa: Forecasted Estimates (till 2035)
21.3.5. Non-Small Cell Lung Cancer Market in Latin America: Forecasted Estimates (till 2035)
21.4. Market Dynamics Assessment
21.4.1. Penetration-Growth (P-G) Matrix
21.5. Data Triangulation and Validation
22. CONCLUDING REMARKS
23. APPENDIX I: TABULATED DATA
24. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS